Stock listing

NASDAQ:CUE Cue Biopharma, Inc. Stock

Home listing (NASDAQ) of Cue Biopharma, Inc.

Follow Cue Biopharma, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:CUE

$4.15 USD -0.35 (-7.8%)

Close on Nov 20, 2026

Past year -74.4% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$4.05 – $4.90 USDNov 20, 2026
Volume
1.26M sharesNov 20, 2026
Market cap
$34.69M USDAt the close on Nov 20, 2026 · price × 8.36M shares outstanding
52-week range
$2.83 – $45.50 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$7.66M USDMedian day 176,136 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Cue Biopharma, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:CUE · Home$4.15 USD-0.35 (-7.8%)1,263,468$4.52$4.90$4.05$4.50Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CUE · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$4.15-0.35-7.8%$4.52$4.90$4.051,263,468
$4.50-0.26-5.5%$4.48$5.16$3.8512,088,520
$4.76+1.93+68.2%$3.41$4.77$3.2713,229,240
$2.83-11.27-79.9%$13.02$13.52$2.834,229,479
$14.10-2.02-12.5%$15.81$15.81$13.56211,343
$16.12-1.38-7.9%$17.69$17.69$14.30274,955
$17.50-1.16-6.2%$18.23$18.92$17.21147,421
$18.66-0.10-0.5%$19.24$19.99$18.51122,973
$18.76-1.38-6.9%$19.73$20.35$18.76132,863
$20.14+1.41+7.5%$18.90$21.20$17.95187,454
$18.73+0.72+4.0%$18.36$19.00$17.85205,562
$18.01-1.83-9.2%$19.35$19.74$16.87141,747
$19.84-1.02-4.9%$20.69$20.99$18.30169,027
$20.86+1.44+7.4%$19.66$21.00$19.01181,890
$19.42-1.45-6.9%$20.74$21.40$19.12140,953
$20.87-0.58-2.7%$20.66$21.17$19.8560,773
$21.45+0.29+1.4%$20.97$22.49$20.7494,697
$21.16+2.84+15.5%$18.46$21.79$18.44157,542
$18.32-0.13-0.7%$18.58$18.82$17.74115,062
$18.45-0.21-1.1%$18.48$18.85$17.89181,714
$18.66-0.23-1.2%$18.88$19.35$18.0479,367
$18.89-0.06-0.3%$18.57$19.48$18.2954,610
$18.95+1.91+11.2%$17.28$19.54$17.28112,329
$17.04+0.96+6.0%$15.98$17.93$15.93169,203
$16.08-0.63-3.8%$17.05$17.63$16.06133,157
$16.71-1.96-10.5%$18.57$18.87$16.54106,567
$18.67+0.07+0.4%$18.53$18.98$17.25229,460
$18.60-0.97-5.0%$20.01$20.79$18.09245,074
$19.57-5.04-20.5%$24.40$25.42$19.50301,826
$24.61-3.05-11.0%$27.44$29.00$24.48179,427
$27.66+5.33+23.9%$22.21$29.00$22.10394,674
$22.33-0.18-0.8%$22.38$22.74$21.60109,897
$22.51-0.63-2.7%$22.92$23.10$22.27133,169
$23.14-1.22-5.0%$24.22$24.89$22.92174,848
$24.36-1.21-4.7%$25.60$25.94$22.21272,651
$25.57+0.32+1.3%$25.60$25.92$24.67157,036
$25.25-0.62-2.4%$26.00$26.03$24.60183,432
$25.87+0.36+1.4%$25.89$27.43$24.88228,119
$25.51-1.94-7.1%$28.15$28.15$24.13283,903
$27.45-3.96-12.6%$30.86$32.07$27.01237,825
$31.41-1.44-4.4%$33.12$33.40$30.75232,443
$32.85+1.14+3.6%$31.15$33.64$30.44330,395
$31.71+0.81+2.6%$29.91$35.23$29.86696,484
$30.90+2.63+9.3%$28.61$32.39$25.491,205,815
$28.27-8.78-23.7%$38.50$41.50$23.803,540,709
$37.05-0.79-2.1%$39.35$41.00$35.54381,952
$37.84+3.67+10.7%$34.75$38.07$34.20195,083
$34.17+2.53+8.0%$31.27$36.47$30.33277,389
$31.64+1.09+3.6%$30.65$32.00$29.26127,172
$30.55+1.81+6.3%$28.24$31.10$28.24136,595
$28.74+0.74+2.6%$28.38$28.89$27.50122,768
$28.00-2.50-8.2%$30.20$30.91$27.50143,189
$30.50+0.50+1.7%$30.00$32.13$30.00174,151
$30.00+2.56+9.3%$27.39$30.24$25.62260,041
$27.44-0.23-0.8%$27.55$27.95$27.0350,416
$27.67+0.71+2.6%$26.60$28.09$26.6065,684
$26.96-1.48-5.2%$28.32$28.93$25.04127,873
$28.44+2.92+11.4%$25.29$29.28$25.01177,424
$25.52-2.36-8.5%$27.48$28.97$25.08101,119
$27.88-0.28-1.0%$28.64$29.75$26.85102,262
$28.16-0.69-2.4%$28.85$29.20$26.38225,518
$28.85+2.09+7.8%$26.63$29.33$26.26205,087
$26.76+3.58+15.4%$23.69$28.29$23.41170,471
$23.18-0.80-3.3%$23.97$24.19$22.56136,572
$23.98-0.63-2.6%$25.55$26.00$23.24177,749
$24.61-1.67-6.4%$26.44$28.11$24.40158,053

Splits

1 split · NASDAQ:CUE · every price before a split is adjusted for it

DayRatioWhat
1-for-30Consolidation
Ticker
NASDAQ:CUE
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Cue Biopharma, Inc. news

Cue Biopharma, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
22 in the last 12 months · 112 in all · newest Nov 16, 2026 · oldest 2019
Calls
8 calls with a replay · 8 with a transcript · latest May 15, 2025
Decks
33 decks · latest September 2026

Where Cue Biopharma, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:CUE · Home listing · This pageNASDAQUnited StatesUSD
BOATS:CUEBOATSUnited StatesUSD
gettex:1UC0gettexGermanyEUR
LS Exchange:A426PNLS ExchangeGermanyEUR
Lang & Schwarz:A426PNLang & SchwarzGermanyEUR
Tradegate:1UC0TradegateGermanyEUR
Frankfurt:1UC0FrankfurtGermanyEUR
Dusseldorf:1UC0DusseldorfGermanyEUR
Munich:1UC0MunichGermanyEUR
Stuttgart:1UC0StuttgartGermanyEUR

Valuation

EV/sales −0.7× against a median of 2.3×: 2nd lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$23.25M USD
P/E
Loss
EV/sales
−0.7×
EV/EBITDA
Negative EBITDA
Price/book
0.9×
Gross margin
Not reported
Operating margin
−387.7%
Net margin
−580.0%
Debt to equity
0.0×
Beta vs S&P 500
2.35

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Cue Biopharma, Inc. · NASDAQ:CUEUS$34.69M−US$23.25Mn/a−0.7×n/a0.9×−580.0%0.0×2.35
TaiRx, Inc. · TPEX:6580US$37.08MUS$28.62Mn/a33.8×n/a3.3×−793.3%0.0×n/a
Pliant Therapeutics, Inc. · NASDAQ:PLRXUS$36.89M−US$104.2Mn/an/an/a0.3×n/a0.0×1.06
Arovella Therapeutics Limited · ASX:ALAUS$36.02MUS$26.52Mn/an/an/a3.8×n/a0.0×n/a
Grace Therapeutics, Inc. · NASDAQ:GRCEUS$35.97MUS$14.66Mn/an/an/a0.7×n/a0.0×0.77
Cantargia AB · OMXSTO:CANTAUS$35.62MUS$13.86M2.2×0.5×0.9×1.4×52.8%0.0×n/a
B&K Corporation Limited Class H · HKEX:2396US$33.15M−US$47.28Mn/a−603×n/a0.4×n/a0.0×n/a
Veru Inc. · NASDAQ:VERUUS$33.08MUS$9.20Mn/an/an/a1.2×n/a0.0×1.92
Actinium Pharmaceuticals, Inc. (Delaware) · AMEX:ATNMUS$33.01MUS$5.49M3.1×n/a0.6×1.3×n/a0.1×0.71
Neurizon Therapeutics Limited · ASX:NUZUS$32.78MUS$26.55Mn/a2.3×n/a3.9×−61.0%0.3×n/a
Transcenta Holding Limited · HKEX:6628US$32.41MUS$52.57Mn/a12.4×n/a0.4×−569.5%0.3×n/a
Median of the othersUS$34.38MUS$14.26M2.6×2.3×0.7×1.3×−315.2%0.0×0.92

Forecasts

3 strong buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
88.00 USD · Analysts' mean
EPS, year to Dec 2026
-25.01 · 3 analysts
Revenue, year to Dec 2026
15.62M · 3 analysts

Team and board

Officers

OfficerRole
Shao-Lee LinPresident, Chief Executive Officer and Board Director
James M. AhlersChief Financial Officer
Sumita RayChief Legal & Compliance Officer & Corporate Secretary
Agnes LeeChief Investor Relations & Communications Officer
Dominic BorieChief Medical Officer & Head of Research & Development
Ron OystonChief Administrative Officer

Board

DirectorRole
Pasha SarrafChairman of the Board
Daniel CamardoBoard Member
Pamela D. GarzoneBoard Member
Shao-Lee LinPresident, Chief Executive Officer and Board Director
Viola MeehanBoard Member

Events

Calls

CallWhenStatus
Cue Biopharma (NASDAQ:CUE) Q1 2025 Earnings CallThu, May 15, 2025 · 11:00 AM ETReplay
Cue Biopharma (NASDAQ:CUE) Q2 2024 Earnings CallMon, Aug 19, 2024 · 4:30 PM ETReplay
Cue Biopharma (NASDAQ:CUE) Q4 2023 Earnings CallMon, Apr 08, 2024 · 4:30 PM ETReplay
Cue Biopharma (NASDAQ:CUE) Q3 2023 Earnings CallThu, Nov 09, 2023 · 4:05 AM ETReplay
Cue Biopharma (NASDAQ:CUE) Q2 2023 Earnings CallWed, Aug 09, 2023 · 4:30 PM ETReplay
Cue Biopharma (NASDAQ:CUE) Q4 2022 Earnings CallTue, Mar 21, 2023 · 4:30 PM ETReplay
Cue Biopharma (NASDAQ:CUE) Q3 2022 Earnings CallMon, Nov 14, 2022 · 4:30 PM ETReplay
Cue Biopharma (NASDAQ:CUE) Q2 2022 Earnings CallTue, Aug 23, 2022 · 4:30 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 16, 2026 · After close−79.9%
Q2 2026Aug 14, 2026 · After close−19.2%
Q1 2026May 14, 2026 · After close−9.2%
Q4 2025Mar 24, 2026−0.8%
Q3 2025Nov 12, 2025 · After close−7.2%
Q2 2025Aug 12, 2025 · After close+2.6%
Q1 2025May 12, 2025 · After close+2.3%
Q4 2024Mar 26, 2025 · After close+0.6%
Q3 2024Nov 14, 2024 · After close−17.0%
Q2 2024Aug 14, 2024 · After close−4.2%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · After close−9.1%
Q4 2023Mar 28, 2024 · After close+0.5%
Q3 2023Nov 3, 2023 · After close+4.1%
Q2 2023Aug 8, 2023 · After close+1.1%
Q1 2023May 9, 2023 · After close−2.5%
Q4 2022Mar 21, 2023 · After close−2.1%
Q3 2022Nov 14, 2022 · After close+16.3%
Q2 2022Aug 4, 2022 · After close0.0%
Q1 2022May 10, 2022 · After close−15.0%
Q4 2021Mar 16, 2022 · After close+19.7%

Open Events

Decks

DeckKindSlidesDate
Technical Presentation (September 2026)Technical23 slidesSeptember 2026
Investor Presentation (July 2026)Investor deck22 slidesJuly 2026
Investor Presentation (June 2026)Investor deck22 slidesJun 3, 2026
Investor Presentation (June 2026)Investor deck11 slidesJun 1, 2026
Investor Presentation (June 2026)Investor deck7 slidesJune 2026
Technical Presentation (April 2026)Technical33 slidesApr 7, 2026
Investor Presentation (February 2026)Investor deck23 slidesFebruary 2026
Investor Presentation (November 2025)Investor deck26 slidesNovember 2025
Corporate Update (April 2025)Corporate update18 slidesApr 15, 2025
ASCO 2024 Oral PresentationConference17 slidesMay 23, 2024
All 33 decks
DeckKindSlidesDate
Oppenheimer Annual Healthcare Life Sciences Conference 2024Conference30 slidesFeb 13, 2024
Investor Presentation (November 2023)Investor deck25 slidesNovember 2023
Investor Presentation (November 2023)Investor deck24 slidesNovember 2023
Investor Presentation (March 2023)Investor deck26 slidesMarch 2023
Q2 2022 Earnings PresentationEarnings19 slidesAug 23, 2022
Investor Presentation (March 2022)Investor deck22 slidesMarch 2022
Investor Presentation (November 2021)Investor deck25 slidesNovember 2021
Investor Presentation (September 2021)Investor deck23 slidesSeptember 2021
Q2 2021 Earnings PresentationEarnings27 slidesAug 17, 2021
Q1 2021 Earnings PresentationEarnings20 slidesMay 17, 2021
Oppenheimer 31st Annual Healthcare Conference 2021Conference26 slidesMar 18, 2021
Q4 2020 Earnings PresentationEarnings27 slidesMar 16, 2021
Investor Presentation (February 2021)Investor deck24 slidesFebruary 2021
Investor Presentation (October 2020)Investor deck20 slidesOctober 2020
Investor Presentation (September 2020)Investor deck19 slidesSeptember 2020
Investor Presentation (July 2020)Investor deck22 slidesJul 20, 2020
Jefferies Virtual Healthcare Conference 2020Conference22 slidesJun 4, 2020
Q1 2020 Earnings PresentationEarnings16 slidesMay 19, 2020
Cowen & Co. 40th Annual Healthcare Conference 2020Conference24 slidesMar 2, 2020
Investor Presentation (January 2020)Investor deck20 slidesJanuary 2020
Investor Presentation (May 2019)Investor deck28 slidesMay 2019
Investor Presentation (May 2018)Investor deck21 slidesMay 17, 2018
IPO Roadshow (December 2017)IPO roadshow18 slidesDec 5, 2017

Open Decks

Financings

RaiseDate
Private placement of common stock and pre-funded warrants
Announced: about US$50M · US$33.21 a share
Buyers: Cormorant Asset Management; Columbia Threadneedle Investments
Use of proceeds: Further fund clinical development and general corporate purposes
Jul 10, 2026
Private placement of pre-funded warrants and accompanying common stock warrants
Announced: about US$30M · US$11 a share · Warrants at US$11 · Newbridge Securities Corporation
Dealers: Newbridge Securities Corporation (lead)
Use of proceeds: Advance the clinical pipeline, including acquiring and developing Ascendant-221, working capital and general corporate purposes
Apr 30, 2026
Public offering of shares of common stock (or pre-funded warrants) and accompanying common stock warrants
Announced: about US$10M · US$0.28 a share · Warrants at US$0.3 for 60 months · H.C. Wainwright & Co. +1
Dealers: H.C. Wainwright & Co. (lead), Newbridge Securities Corporation
Dec 19, 2025
Public offering of common stock and accompanying common stock warrants, pre-funded warrants
Closed: US$20M raised · US$0.79 a share · Warrants at US$0.79 for 60 months · Oppenheimer & Co. Inc. +1
Dealers: Oppenheimer & Co. Inc. (lead), Newbridge Securities Corporation
Aug 12, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$7.50 a share on Dec 14, 2017.

Price
US$7.50 a share
Listing
CUE on the Nasdaq Capital Market
Underwriters
MDB Capital Group, LLC, Feltl and Company · In the order on the cover

Steps

StepWhen
Filed publiclySep 21, 2017
Amended 5 timesNewest Dec 13, 2017
Shares registered with an exchangeDec 13, 2017
Declared effective by the SECDec 14, 2017
Final prospectus, with the priceDec 21, 2017

Open IPO · From the cover of the final prospectus (424B1) filed Dec 21, 2017

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue27.5M9.29M5.49M1.25M14.9M3.15M3.46M1.14M00
Cost of revenue3.48M2.35M38.1M1.81M-1.78M33.5M27.5M28.5M419.6K202.1K
Gross profit27.5M9.29M-32.6M1.25M14.9M-30.4M3.46M-27.4M-419.6K-202.1K
Research and development37.7M36.3M40.8M38.6M41.3M33.5M27.5M28.5M18.9M5.69M
Selling, general and administrative16.2M14.6M16.7M16.2M17.3M14.7M12.7M11.3M4.33M1.97M
Operating income-26.6M-41.5M-52.1M-53.2M-43.7M-45.0M-36.8M-38.7M-23.2M-7.66M
Depreciation and amortization958.0K397.0K556.0K922.0K1.26M1.06M810.8K760.0K419.6K202.1K
EBITDA-25.6M-41.1M-51.6M-52.3M-42.5M-44.0M-36.0M-37.9M-22.8M-7.46M
Interest expense100.0K100.0K100.0K109.0K1.73M463.9K5.65M000
Income before tax-26.1M-40.7M-50.7M-53.0M-43.7M-44.6M-36.3M-38.2M-23.2M-7.66M
Income tax500.0K03.27M0495.0K206.3K412.5K825.0K00
Net income-26.6M-40.7M-50.7M-53.0M-44.2M-44.8M-36.7M-39.0M-23.2M-7.66M
Earnings per share, basic-0.28-0.72-1.11-1.49-1.41-1.56-1.66-1.94-2.16-11.13
Earnings per share, diluted-0.28-0.72-1.11-1.49-1.41-1.56-1.66-1.94-2.16

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents27.1M22.5M48.5M51.6M64.4M74.9M44.3M20.8M63.5M14.9M
Short-term investments0024.7M010.0M15.1M18.4M050.0K
Receivables5.55M945.0K1.70M57.0K3.14M1.42M754.9K852.4K
Inventory11115.1M225.5K
Current assets37.0M25.1M51.5M77.2M68.5M87.5M61.0M40.6M65.1M15.1M
Property, plant and equipment241.0K471.0K795.0K1.50M2.11M2.11M1.85M2.78M1.69M1.02M
Total assets42.2M32.2M61.5M91.3M83.4M99.5M71.6M45.4M67.0M16.3M
Accounts payable3.95M2.82M3.50M2.73M2.59M2.07M882.7K2.04M1.66M523.8K
Current liabilities13.5M13.7M17.1M11.5M12.8M16.3M11.7M6.22M5.35M1.07M
Long-term debt04.20M8.04M0
Total debt4.20M37.0K4.04M8.07M07.15M5.80M2.50M
Total liabilities15.8M14.7M24.4M25.6M17.9M20.6M17.0M11.4M5.35M1.10M
Shareholders' equity26.4M17.5M37.1M65.7M65.5M78.9M54.6M34.0M61.6M15.2M
Shares outstanding3.22M61.8M47.2M47.2M32.2M30.4M26.6M20.7M19.5M688.0K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-21.7M-36.3M-40.0M-41.8M-38.8M-32.5M-30.8M-26.4M-12.1M-5.97M
Capital spending-177.0K-66.0K0-171.0K-913.0K-595.3K-46.4K-1.85M-1.03M-516.0K
Free cash flow-21.9M-36.4M-40.0M-42.0M-39.8M-33.1M-30.8M-28.3M-13.2M-6.48M
Cash from investing75.0K32.0K25.0M-24.6M9.11M4.46M3.45M-20.4M-1.20M-516.0K
Cash from financing26.3M10.2M11.9M53.7M19.2M58.6M50.8M4.18M62.0M15.0M
Dividends paid-199.9K
Share buybacks0-200.0K-750.1K-271.1K-91.0K4.18M-4.16M-1.41M
Change in cash4.68M-26.1M-3.10M-12.8M-10.5M30.6M23.4M-42.6M48.7M8.52M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 16, 2026Quarterly reportSEC
8-K · Current reportNov 16, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 10, 2026Big-stake noticeSEC
4 · Change in ownershipOct 14, 2026Insider tradeSEC
4 · Change in ownershipOct 14, 2026Insider tradeSEC
4 · Change in ownershipOct 14, 2026Insider tradeSEC
144 · Notice of proposed saleOct 13, 2026Other filingsSEC
Show 200 filings
FilingDateTypeFiled with
144 · Notice of proposed saleOct 13, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 8, 2026Big-stake noticeSEC
8-K · Current reportSep 21, 2026Current reportSEC
4/A · Change in ownership, amendedAug 28, 2026Insider tradeSEC
4/A · Change in ownership, amendedAug 28, 2026Insider tradeSEC
SCHEDULE 13D · Big-stake noticeAug 21, 2026Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveAug 21, 2026Other filingsSEC
CORRESP · Letter to the SECAug 18, 2026Other filingsSEC
4 · Change in ownershipAug 17, 2026Insider tradeSEC
4 · Change in ownershipAug 17, 2026Insider tradeSEC
UPLOAD · Letter from the SECAug 17, 2026Other filingsSEC
4 · Change in ownershipAug 14, 2026Insider tradeSEC
144 · Notice of proposed saleAug 14, 2026Other filingsSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
8-K · Current reportAug 14, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
144 · Notice of proposed saleAug 13, 2026Other filingsSEC
S-3 · Registration statementAug 12, 2026Offer documentSEC
8-K · Current reportAug 3, 2026Management or board changeSEC
4 · Change in ownershipAug 3, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 3, 2026Insider tradeSEC
4/A · Change in ownership, amendedJul 30, 2026Insider tradeSEC
DJul 22, 2026Other filingsSEC
4 · Change in ownershipJul 15, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 15, 2026Insider tradeSEC
4 · Change in ownershipJul 10, 2026Insider tradeSEC
4 · Change in ownershipJul 10, 2026Insider tradeSEC
4 · Change in ownershipJul 10, 2026Insider tradeSEC
4 · Change in ownershipJul 10, 2026Insider tradeSEC
4 · Change in ownershipJul 10, 2026Insider tradeSEC
4 · Change in ownershipJul 10, 2026Insider tradeSEC
4 · Change in ownershipJul 10, 2026Insider tradeSEC
8-K · Current reportJul 10, 2026Material contractSEC
EFFECT · Notice that a registration is effectiveJul 2, 2026Other filingsSEC
CORRESP · Letter to the SECJun 29, 2026Other filingsSEC
UPLOAD · Letter from the SECJun 25, 2026Other filingsSEC
S-3 · Registration statementJun 18, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveJun 18, 2026Other filingsSEC
CORRESP · Letter to the SECJun 15, 2026Other filingsSEC
3 · Initial statement of ownershipJun 11, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 11, 2026Insider tradeSEC
UPLOAD · Letter from the SECJun 10, 2026Other filingsSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
8-K · Current reportJun 3, 2026Management or board changeSEC
S-8 · Registration statement for employee plansJun 3, 2026Offer documentSEC
S-3 · Registration statementJun 3, 2026Offer documentSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 2, 2026Insider tradeSEC
8-K · Current reportJun 2, 2026Management or board changeSEC
DEF 14A · Proxy statementMay 21, 2026Meeting noticeSEC
8-K · Current reportMay 14, 2026Current reportSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
DMay 14, 2026Other filingsSEC
PRE 14A · Preliminary proxy statementMay 12, 2026Meeting noticeSEC
3 · Initial statement of ownershipMay 7, 2026Insider tradeSEC
4 · Change in ownershipMay 7, 2026Insider tradeSEC
S-8 · Registration statement for employee plansApr 30, 2026Offer documentSEC
8-K · Current reportApr 30, 2026Material contractSEC
8-K · Current reportApr 22, 2026Current reportSEC
8-K · Current reportApr 13, 2026Meeting outcomeSEC
4 · Change in ownershipApr 10, 2026Insider tradeSEC
4 · Change in ownershipApr 10, 2026Insider tradeSEC
4 · Change in ownershipApr 10, 2026Insider tradeSEC
8-K · Current reportApr 7, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveApr 1, 2026Other filingsSEC
CORRESP · Letter to the SECMar 27, 2026Other filingsSEC
DEFA14A · Additional proxy materialMar 27, 2026Meeting noticeSEC
8-K · Current reportMar 27, 2026Management or board changeSEC
UPLOAD · Letter from the SECMar 23, 2026Other filingsSEC
S-3 · Registration statementMar 17, 2026Offer documentSEC
ARS · Annual report to shareholdersMar 16, 2026Annual reportSEC
DEF 14A · Proxy statementMar 16, 2026Meeting noticeSEC
8-K · Current reportMar 16, 2026ResultsSEC
10-K · Annual reportMar 16, 2026Annual reportSEC
PRE 14A · Preliminary proxy statementMar 6, 2026Meeting noticeSEC
8-K · Current reportFeb 18, 2026Current reportSEC
8-K · Current reportFeb 12, 2026Management or board changeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
144 · Notice of proposed saleDec 29, 2025Other filingsSEC
8-K · Current reportDec 19, 2025Material contractSEC
424B5 · ProspectusDec 19, 2025Offer documentSEC
424B5 · ProspectusDec 18, 2025Offer documentSEC
4 · Change in ownershipDec 5, 2025Insider tradeSEC
4 · Change in ownershipNov 25, 2025Insider tradeSEC
4 · Change in ownershipNov 25, 2025Insider tradeSEC
8-K · Current reportNov 24, 2025Current reportSEC
8-K · Current reportNov 20, 2025Management or board changeSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
8-K · Current reportNov 12, 2025ResultsSEC
8-K · Current reportNov 6, 2025Material contractSEC
4 · Change in ownershipOct 2, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 2, 2025Insider tradeSEC
8-K · Current reportSep 29, 2025Management or board changeSEC
S-8 · Registration statement for employee plansAug 12, 2025Offer documentSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
8-K · Current reportAug 12, 2025ResultsSEC
8-K · Current reportJul 1, 2025Material contractSEC
8-K · Current reportJun 10, 2025Management or board changeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 6, 2025Insider tradeSEC
DEFA14A · Additional proxy materialMay 27, 2025Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 16, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 12, 2025Quarterly reportSEC
8-K · Current reportMay 12, 2025ResultsSEC
ARS · Annual report to shareholdersApr 25, 2025Annual reportSEC
DEF 14A · Proxy statementApr 25, 2025Meeting noticeSEC
DEFA14A · Additional proxy materialApr 25, 2025Meeting noticeSEC
8-K · Current reportApr 15, 2025ResultsSEC
424B5 · ProspectusApr 15, 2025Offer documentSEC
424B5 · ProspectusApr 14, 2025Offer documentSEC
8-K · Current reportApr 14, 2025Material contractSEC
PRE 14A · Preliminary proxy statementApr 14, 2025Meeting noticeSEC
S-8 · Registration statement for employee plansMar 31, 2025Offer documentSEC
8-K · Current reportMar 31, 2025ResultsSEC
10-K · Annual reportMar 31, 2025Annual reportSEC
4 · Change in ownershipMar 25, 2025Insider tradeSEC
4 · Change in ownershipMar 25, 2025Insider tradeSEC
4 · Change in ownershipMar 25, 2025Insider tradeSEC
4 · Change in ownershipMar 25, 2025Insider tradeSEC
4 · Change in ownershipMar 25, 2025Insider tradeSEC
4 · Change in ownershipMar 25, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 21, 2025Big-stake noticeSEC
8-K · Current reportMar 12, 2025Management or board changeSEC
4 · Change in ownershipMar 12, 2025Insider tradeSEC
3 · Initial statement of ownershipMar 12, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipDec 18, 2024Insider tradeSEC
UPLOAD · Letter from the SECDec 16, 2024Other filingsSEC
CORRESP · Letter to the SECDec 11, 2024Other filingsSEC
UPLOAD · Letter from the SECDec 5, 2024Other filingsSEC
4 · Change in ownershipNov 29, 2024Insider tradeSEC
3 · Initial statement of ownershipNov 29, 2024Insider tradeSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
8-K · Current reportNov 14, 2024ResultsSEC
8-K · Current reportOct 8, 2024Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 7, 2024Big-stake noticeSEC
8-K · Current reportOct 4, 2024Material contractSEC
8-K · Current reportSep 27, 2024Material contractSEC
424B5 · ProspectusSep 27, 2024Offer documentSEC
424B5 · ProspectusSep 26, 2024Offer documentSEC
DEF 14A · Proxy statementSep 10, 2024Meeting noticeSEC
3 · Initial statement of ownershipSep 5, 2024Insider tradeSEC
4 · Change in ownershipSep 5, 2024Insider tradeSEC
8-K · Current reportSep 3, 2024Management or board changeSEC
PRE 14A · Preliminary proxy statementAug 28, 2024Meeting noticeSEC
8-K · Current reportAug 16, 2024Current reportSEC
10-Q · Quarterly reportAug 14, 2024Quarterly reportSEC
8-K · Current reportJul 25, 2024Management or board changeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
8-K · Current reportJun 7, 2024Management or board changeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
3 · Initial statement of ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
DEFA14A · Additional proxy materialMay 24, 2024Meeting noticeSEC
8-K · Current reportMay 9, 2024ResultsSEC
10-Q · Quarterly reportMay 9, 2024Quarterly reportSEC
DEF 14A · Proxy statementApr 26, 2024Meeting noticeSEC
DEFA14A · Additional proxy materialApr 26, 2024Meeting noticeSEC
ARS · Annual report to shareholdersApr 26, 2024Annual reportSEC
S-8 · Registration statement for employee plansMar 28, 2024Offer documentSEC
10-K · Annual reportMar 28, 2024Annual reportSEC
SC 13G · Big-stake noticeMar 11, 2024Big-stake noticeSEC
4 · Change in ownershipMar 8, 2024Insider tradeSEC
4 · Change in ownershipMar 8, 2024Insider tradeSEC
4 · Change in ownershipMar 8, 2024Insider tradeSEC
4 · Change in ownershipMar 8, 2024Insider tradeSEC
4 · Change in ownershipMar 8, 2024Insider tradeSEC
4 · Change in ownershipFeb 22, 2024Insider tradeSEC
SC 13G · Big-stake noticeFeb 7, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeJan 31, 2024Big-stake noticeSEC
4 · Change in ownershipJan 4, 2024Insider tradeSEC
4 · Change in ownershipJan 4, 2024Insider tradeSEC
4 · Change in ownershipJan 4, 2024Insider tradeSEC
4 · Change in ownershipJan 4, 2024Insider tradeSEC
4 · Change in ownershipJan 4, 2024Insider tradeSEC

This page holds 200 of 558 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Cue Biopharma, Inc.’s releases · as of Nov 13, 2026

Common shares
8,359,523
Fully diluted
8,359,523

Fully diluted

LineSharesAs of
Common shares8,359,523Nov 13, 2026

Warrants and options

Lot
Warrants · US$0.79 · expire about Apr 2030

Share count over time

CountShares
Nov 13, 20268,359,523

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueChange vs Jun 30Filed
Ameriprise660K7.9%US$17.1MNewNov 16, 2026
Cormorant Asset Management, LP625K7.5%US$16.2MNewNov 16, 2026
Balyasny Asset Management L.P.427K5.1%US$11.1MNewNov 16, 2026
Bleichroeder LP366K4.4%US$9.47M−4,530Nov 13, 2026
Vanguard354K4.2%US$9.16M+166KNov 13, 2026
Driehaus Capital Management LLC292K3.5%US$7.56MNo changeNov 16, 2026
Ikarian Capital, LLC291K3.5%US$7.52M+186KNov 16, 2026
Vivo Capital, LLC280K3.4%US$7.25MNewNov 13, 2026
Morgan Stanley204K2.4%US$5.28M+203KNov 13, 2026
Adage Capital Partners Gp, L.L.C.200K2.4%US$5.17MNewNov 16, 2026
Show 50 holders
HolderSharesOf the companyValueChange vs Jun 30Filed
UBS111K1.3%US$2.88M+84,796Nov 10, 2026
Stempoint Capital LP109K1.3%US$2.81M+41,652Nov 16, 2026
Nantahala Capital Management, LLC96,0491.1%US$2.48MNewNov 13, 2026
Boothbay Fund Management, LLC87,3301.0%US$2.26M+55,871Nov 16, 2026
Geode Capital68,9110.82%US$1.78M+21,087Nov 6, 2026
BlackRock55,3690.66%US$1.43M−2,438Nov 13, 2026
Lion Point Capital, LP52,9280.63%US$1.37MNo changeNov 16, 2026
Millennium44,3560.53%US$1.15MNewNov 16, 2026
ADAR1 Capital Management, LLC43,9350.53%US$1.14M−11,258Nov 16, 2026
Bank of America36,0960.43%US$934K+29,167Nov 16, 2026
Jane Street36,0710.43%US$933KNewNov 12, 2026
State Street31,9760.38%US$827KNewNov 12, 2026
Texas Capital Bank Wealth Management Services Inc27,3450.33%US$707K+4,464Nov 9, 2026
Eversept Partners, LP22,1210.26%US$572KNewNov 16, 2026
Citadel19,8080.24%US$512K−5,825Nov 16, 2026
Prudential Financial Inc19,0850.23%US$494KNewNov 16, 2026
Squarepoint Ops LLC16,8020.20%US$435KNewNov 9, 2026
Northern Trust14,7870.18%US$383K+5,665Nov 16, 2026
XTX Topco Ltd14,5190.17%US$376KNewNov 16, 2026
Stifel Financial Corp11,5550.14%US$299K+3,337Nov 12, 2026
Robertson Stephens Wealth Management, LLC11,1330.13%US$288KNo changeOct 16, 2026
Renaissance Technologies10,2890.12%US$266K−4,400Nov 12, 2026
Persistent Asset Partners Ltd9,9310.12%US$257K−2,401Nov 12, 2026
Goldman Sachs9,4120.11%US$243KNewNov 16, 2026
Advisory Research Inc8,5730.10%US$222KNo changeNov 12, 2026
Citigroup Inc3,1190.04%US$80,689+3,118Nov 4, 2026
Barclays2,8350.03%US$73,341+2,356Nov 6, 2026
Northwestern Mutual Wealth Management Co2,6320.03%US$68,090No changeNov 13, 2026
Aster Capital Management (DIFC) Ltd2,1110.03%US$54,612NewNov 12, 2026
Osaic Holdings, Inc.1,0480.01%US$26,749+1,000Nov 12, 2026
US Bancorp \de\400<0.01%US$10,348NewNov 5, 2026
SBI Securities Co., Ltd.300<0.01%US$7,761No changeOct 21, 2026
Gleason Group, Inc.200<0.01%US$5,174No changeOct 15, 2026
Tower Research Capital LLC (TRC)172<0.01%US$4,450−697Nov 16, 2026
RBC103<0.01%US$3,000+101Nov 16, 2026
NFSG Corp99<0.01%US$2,561No changeOct 15, 2026
Golden State Wealth Management, LLC66<0.01%US$1,707No changeNov 2, 2026
Tidemark, LLC50<0.01%US$1,294No changeNov 9, 2026
Physician Wealth Advisors, Inc.33<0.01%US$854No changeOct 20, 2026
Mather Group, LLC.33<0.01%US$854No changeOct 14, 2026

This page holds 50 of 56 holders. Open Shareholders

Funds

HolderSharesOf the companyValueChangeAs of
Vanguard Total Stock Market Index Fund112K1.3%US$3.53MNewJun 30, 2026
Vanguard Extended Market Index Fund47,0900.56%US$1.49MNewJun 30, 2026
Fidelity Extended Market Index Fund16,0310.19%US$351KNewMay 31, 2026
iShares Micro-Cap ETF11,1290.13%US$351KNewJun 30, 2026
Fidelity Total Market Index Fund5,7830.07%US$127KNewMay 31, 2026
Fidelity Series Total Market Index Fund4,8120.06%US$105KNewMay 31, 2026
Dimensional U.S. Small Cap ETF1,8150.02%US$48,715NewJul 31, 2026
Vanguard Balanced Index Fund1,7240.02%US$54,409NewJun 30, 2026
Vanguard Institutional Total Stock Market Index Fund1,0190.01%US$32,160NewJun 30, 2026
Fidelity Nasdaq Composite Index Fund9750.01%US$21,353NewMay 31, 2026
All 16 holders
HolderSharesOf the companyValueChangeAs of
1290 VT Micro Cap Portfolio747<0.01%US$23,575NewJun 30, 2026
Avantis U.S. Small Cap Equity ETF300<0.01%US$6,570NewMay 31, 2026
Dimensional US Core Equity Market ETF116<0.01%US$3,113NewJul 31, 2026
U.S. Micro Cap Portfolio105<0.01%US$2,818NewJul 31, 2026
Total Stock Market Index Trust59<0.01%US$1,862NewJun 30, 2026
Avantis Total Equity Markets ETF10<0.01%US$219NewMay 31, 2026

Insider trades

InsiderTradeSharesPriceValueDate
Ray Sumita
Officer: Chief Legal Compliance Officer, Other: Corporate Secretary
Sale1,844USD 28.05US$51,724Oct 12, 2026
Lin Shao-Lee
Director, Officer: Chief Executive Officer
Sale10,000USD 27.50US$275KOct 12, 2026
Lin Shao-Lee
Director, Officer: Chief Executive Officer
Sale1,087USD 28.05US$30,490Oct 12, 2026
Meluzio Michael Vincent
Officer: VP, Prin. Accounting Officer
Sale1,144USD 28.05US$32,089Oct 12, 2026
Ray Sumita
Officer: Chief Legal Compliance Officer, Other: Corporate Secretary
Sale2,383USD 29.37US$69,989Aug 13, 2026
Ray Sumita
Officer: Chief Legal Compliance Officer, Other: Corporate Secretary
Sale6,442USD 30.35US$196KAug 13, 2026
Ray Sumita
Officer: Chief Legal Compliance Officer, Other: Corporate Secretary
Sale4USD 31.13US$125Aug 13, 2026
Meluzio Michael Vincent
Officer: VP, Prin. Accounting Officer
Sale1,519USD 29.37US$44,613Aug 13, 2026
Meluzio Michael Vincent
Officer: VP, Prin. Accounting Officer
Sale4,106USD 30.35US$125KAug 13, 2026
Meluzio Michael Vincent
Officer: VP, Prin. Accounting Officer
Sale3USD 31.13US$93Aug 13, 2026
All 15 trades
InsiderTradeSharesPriceValueDate
Lin Shao-Lee
Director, Officer: Chief Executive Officer
Sale5,423USD 27.19US$147KAug 13, 2026
Lin Shao-Lee
Director, Officer: Chief Executive Officer
Sale2,375USD 28.11US$66,761Aug 13, 2026
Lin Shao-Lee
Director, Officer: Chief Executive Officer
Sale10,460USD 29.48US$308KAug 13, 2026
Lin Shao-Lee
Director, Officer: Chief Executive Officer
Sale34,225USD 26.99US$924KAug 12, 2026
Lin Shao-Lee
Director, Officer: Chief Executive Officer
Sale5,775USD 27.75US$160KAug 12, 2026

Big stakes

HolderStakeSharesDate
Cormorant Asset Management, LP9.99%791KSep 30, 2026
Shao-Lee Lin6.20%467KMay 3, 2026
Balyasny Asset Management L.P.5.88%427KSep 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Frederick W. Driscoll
Other companies: Lite Strategy, Inc. (Chairperson, Non-Executive Director · Since at least Feb 22, 2018); Cellectar Biosciences, Inc. (Director · Since at least Apr 10, 2017); Invivyd, Inc. (Interim CFO · Oct 13, 2022 – Oct 13, 2022 · Past); ConforMIS Inc (INTERIM CFO & INTERIM TREAS · Oct 23, 2019 – Oct 23, 2019 · Past); ImmunityBio, Inc. (Director · Sep 18, 2017 – Aug 11, 2020 · Past); Flexion Therapeutics Inc (Chief Financial Officer · Feb 11, 2014 – Nov 19, 2021 · Past); Oncotelic Therapeutics Inc (Director · Jan 1, 2014 – Jun 1, 2016 · Past); Novavax, Inc. (VP, CFO & Treasurer · Aug 24, 2009 – Mar 2, 2013 · Past); Genelabs Technologies Inc (CEO/PRESIDENT · Nov 1, 2007 – Jan 7, 2009 · Past)
Director · Jun 26, 2018 – Jan 2, 2025 · Past
Anthony DiGiandomenico
Other companies: Illumination Acquisition Corp I (Director · Since at least Feb 26, 2026); ClearSign Technologies Corporation (Director · Since at least May 22, 2025); eXoZymes Inc. (Board Member · Since at least Nov 8, 2024); MDB Capital Holdings, LLC (Co-Founder, Head of New Venture Discovery · Since at least Jul 25, 2023); ENDRA Life Sciences Inc. (Director · Since at least May 8, 2017); Provention Bio Inc (Director · Jul 3, 2018 – May 15, 2020 · Past); Charlie's Holdings, Inc. (Director · Aug 4, 2006 – Aug 27, 2012 · Past)
Director · Dec 18, 2017 – Jan 2, 2019 · Past
Aaron G.L. Fletcher
Other companies: Actuate Therapeutics, Inc. (Chairman · Since at least Aug 12, 2024); Cognition Therapeutics, Inc. (Director · Since at least Oct 7, 2021); IN8bio, Inc. (Director · Aug 16, 2022 – Dec 12, 2022 · Past); TFF Pharmaceuticals Inc (Director · Oct 24, 2019 – Dec 29, 2022 · Past); SWK Holdings Corp (Director · Sep 3, 2019 – Dec 31, 2021 · Past)
Director · Oct 3, 2019 – Jan 3, 2023 · Past
Shao-Lee Lin
Other companies: Acelyrin, Inc. (Chief Executive Officer, Director · May 4, 2023 – Apr 1, 2024 · Past); Third Harmonic Bio Inc. (Director · Sep 14, 2022 – Oct 26, 2022 · Past); Surrozen, Inc. (Director · Aug 11, 2021 – May 14, 2025 · Past); Principia Biopharma Inc (Director · Apr 16, 2019 – Sep 28, 2020 · Past); Horizon Pharma PLC (EVP, Head of R&D and CSO · Jan 4, 2018 – Feb 20, 2019 · Past)
President, Chief Executive Officer and Board Director · Since at least Apr 30, 2026
Sumita Ray
Other companies: Biomea Fusion, Inc. (Director · Since at least Jun 16, 2021); Vaxxinity, Inc. (Chief Legal, Comp & Admin Off · Oct 1, 2023 – Nov 1, 2023 · Past); Instil Bio, Inc. (Chief Legal and Admin Officer · May 3, 2022 – Jan 8, 2023 · Past); Calithera Biosciences, Inc. (See Remarks · Sep 29, 2017 – Jan 25, 2022 · Past); Pharmacyclics Inc (Chief Compliance Officer · Jun 24, 2013 – Oct 31, 2013 · Past)
Chief Legal & Compliance Officer & Corporate Secretary · Since at least Jun 1, 2026
Jill Marie Broadfoot
Other companies: Talphera, Inc. (Director · Since at least Nov 20, 2021); aTyr Pharma, Inc. (Chief Financial Officer · Since at least Jul 30, 2018); Otonomy Inc (Director · Aug 18, 2021 – Jun 21, 2022 · Past); Vical Incorporated (Sr Vice President, CFO, Sec · Jan 7, 2011 – Apr 1, 2013 · Past)
Director · Since at least Jun 4, 2025
Peter A Kiener
Other companies: LAVA Therapeutics NV (Director · Since at least Jan 1, 2025); Palvella Therapeutics, Inc. (Director · Sep 7, 2018 – Jun 21, 2023 · Past); Sucampo Pharmaceuticals Inc (Chief Science Officer · Mar 4, 2015 – Feb 13, 2018 · Past); Medimmune Inc (SVP, Research · Feb 8, 2006 – Feb 23, 2006 · Past)
Director · Since at least Dec 18, 2017
Tamar D Howson
Other companies: Immunic, Inc. (Director · Since at least Oct 11, 2019); Lite Strategy, Inc. (Director · Jul 1, 2019 – Sep 29, 2023 · Past); VivoSim Labs, Inc. (Director · Jul 26, 2018 – Jul 26, 2018 · Past)
Director · Sep 17, 2020 – Jan 3, 2023 · Past
Barry Simon
Other companies: ImmunityBio, Inc. (Chief Corporate Affairs Officer · Since at least Jul 27, 2015); Viracta Therapeutics Inc (Director · Mar 3, 2021 – Jun 20, 2024 · Past)
Director · Dec 18, 2017 – Jan 4, 2021 · Past
Cameron Gray
Other companies: Provention Bio Inc (Director · Jul 3, 2018 – Jul 19, 2018 · Past); Endeavor IP Inc (CEO, CFO, Secretary, Treasurer, Director · May 13, 2013 – May 13, 2013 · Past)
Director · Dec 18, 2017 – Jun 14, 2022 · Past
All 39 people
PersonSeat
Christopher Marlett
Other companies: eXoZymes Inc. (Chairman of the Board · Since at least Nov 8, 2024); MDB Capital Holdings, LLC (Chief Executive Officer, Chairman of Board and Director · Since at least Jul 25, 2023)
Director · Dec 18, 2017 – Jan 2, 2020 · Past
Daniel Baker
Other companies: Shattuck Labs, Inc. (Director · Since at least Aug 25, 2025); Artiva Biotherapeutics, Inc. (Director · Since at least Jan 28, 2025)
CHIEF DEVELOPMENT OFFICER · Since at least Nov 25, 2024
James M. Ahlers
Other companies: Intensity Therapeutics, Inc. (Executive Vice President · Since at least Jun 29, 2023); RenovoRx, Inc. (Chief Financial Officer · Jul 15, 2022 – Jul 15, 2022 · Past)
Chief Financial Officer · Since at least Jul 30, 2026
Michael J Fox
Other companies: Resonant Inc (Director · Feb 16, 2016 – Mar 28, 2022 · Past); Regional Health Properties, Inc. (Director · Oct 1, 2013 – Apr 24, 2018 · Past)
Director · Jun 5, 2024 – Jun 5, 2024 · Past
Daniel R Passeri
Other companies: Curis, Inc. (Director · May 31, 2006 – Jan 19, 2016 · Past)
CHIEF EXECUTIVE OFFICER, Director · Dec 18, 2017 – Mar 21, 2025 · Past
Dominique Christian Borie
Other companies: Kyverna Therapeutics, Inc. (See Remarks · Feb 7, 2024 – Feb 7, 2024 · Past)
Chief Medical Officer · Since at least Jul 13, 2026
Frank Morich
Other companies: Perspective Therapeutics, Inc. (Director · Since at least Feb 3, 2023)
Director · Since at least Jul 31, 2018
Gary Schuman
Other companies: MDB Capital Holdings, LLC (Head of Compliance · Since at least Nov 5, 2026)
Interim CFO · Dec 18, 2017 – Dec 18, 2017 · Past
Kenneth Pienta
Other companies: Curis, Inc. (Director · Mar 7, 2013 – Feb 28, 2017 · Past)
Chief Medical Officer · Dec 18, 2017 – Mar 25, 2022 · Past
Agnes LeeChief Investor Relations & Communications Officer · Since at least Sep 20, 2026
Anish SuriPRESIDENT AND CSO · May 14, 2018 – Jun 5, 2024 · Past
Bethany MancillaSVP and Chief Business Officer · Aug 1, 2018 – Mar 6, 2019 · Past
Colin SandercockSVP, GENERAL COUNSEL · Since at least Dec 18, 2017
Daniel CamardoBoard Member · Since at least May 30, 2026
Dominic BorieChief Medical Officer & Head of Research & Development · Since at least Jul 13, 2026
Kerri-Ann MillarCHIEF FINANCIAL OFFICER · May 1, 2018 – Mar 21, 2025 · Past
Lucinda WarrenCHIEF BUSINESS OFFICER · Since at least Sep 3, 2024
Matteo LevisettiChief Medical Officer · Jan 17, 2023 – Mar 21, 2025 · Past
Michael Vincent MeluzioVP, Prin. Accounting Officer · Since at least Jun 1, 2026
Pamela D. GarzoneBoard Member · Since at least Apr 19, 2023
Pasha SarrafChairman of the Board · Since at least Mar 10, 2025
Patricia NasshornChief Business Officer · Dec 15, 2021 – Feb 16, 2023 · Past
Patrick VerheyenDirector · Since at least Apr 11, 2023
Rodolfo ChaparroEVP, Head of Immunology · Dec 18, 2017 – Jul 23, 2018 · Past
Ronald D Seidel IIIEVP, Head of R&D · Dec 18, 2017 – Jul 23, 2018 · Past
Ron OystonChief Administrative Officer · Since at least Nov 4, 2026
Steven L McKnightDirector · Dec 18, 2017 – Jan 6, 2020 · Past
Usman AzamCHIEF EXECUTIVE OFFICER, Director · Since at least Sep 29, 2025
Viola MeehanBoard Member · Since at least May 30, 2026

Open People

Log in to ask 6ix AI your own questions about Cue Biopharma, Inc.